Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-08-30 Purchase |
2023-08-31 6:42 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
82,052 | $1.315 | $107,898 | 4,215,712 (Indirect Direct) |
View |
| 2023-08-15 Purchase |
2023-08-17 6:08 pm |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
250,000 | $1.3029 | $325,737 | 4,133,660 (Indirect Direct) |
View |
| 2023-08-10 Purchase |
2023-08-11 4:15 pm |
Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer |
88,000 | $1.26 | $110,880 | 448,911 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:23 pm |
Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer |
80,000 | $1.24 | $99,200 | 360,911 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:21 pm |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer |
71,762 | $1.22 | $87,550 | 201,555 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:18 pm |
Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director |
8,000 | $1.23 | $9,840 | 8,000 (Direct) |
View |
| 2023-03-06 Sale |
2023-03-06 6:55 pm |
Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP |
1,871 | $0.98 | $1,834 | 27,440 (Direct) |
View |
| 2022-06-06 Sale |
2022-06-08 4:09 pm |
Cortexyme Inc. | CRTX | McDowell Caryn Gordon Chief Legal & Adm. Officer |
10,800 | $2.8632 | $30,923 | 122,500 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2023-09-06 5:40 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Ryan Charles S. President |
0 | $0 | 74,074 (Direct) |
View |
| 2023-05-24 Option Award |
2023-05-26 5:53 pm |
N/A 2033-05-23 |
Quince Therapeutics Inc. | QNCX | Senner Christopher J. Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2023-05-24 Option Award |
2023-05-26 5:50 pm |
N/A 2033-05-23 |
Quince Therapeutics Inc. | QNCX | RYAN UNA S Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2023-05-24 Option Award |
2023-05-26 5:49 pm |
N/A 2033-05-23 |
Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2023-05-24 Option Award |
2023-05-26 5:47 pm |
N/A 2033-05-23 |
Quince Therapeutics Inc. | QNCX | Lamond David Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2023-05-24 Option Award |
2023-05-26 5:45 pm |
N/A 2033-05-23 |
Quince Therapeutics Inc. | QNCX | Bray June Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 6:37 pm |
N/A 2033-01-31 |
Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer |
600,000 | $0 | 600,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 6:35 pm |
N/A 2033-01-31 |
Quince Therapeutics Inc. | QNCX | Smith Karen L. Chief Medical Officer |
225,000 | $0 | 225,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 6:32 pm |
N/A 2033-01-31 |
Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP |
110,000 | $0 | 110,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 6:29 pm |
N/A 2033-01-31 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer |
225,000 | $0 | 225,000 (Direct) |
View |
| 2022-12-05 Tax Withholding |
2022-12-07 5:37 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP |
1,640 | $0.72 | 29,311 (Direct) |
View |
| 2022-09-06 Tax Withholding |
2022-09-08 5:58 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP |
1,520 | $1.64 | 30,951 (Direct) |
View |
| 2022-06-29 Option Award |
2022-07-01 5:03 pm |
N/A 2032-06-28 |
Cortexyme Inc. | CRTX | Monohon Ted Chief Accounting Officer & VP |
250,000 | $0 | 250,000 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-10 4:20 pm |
N/A 2032-06-08 |
Cortexyme Inc. | CRTX | Bray June Director |
54,000 | $0 | 54,000 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-09 8:48 pm |
N/A 2032-06-07 |
Cortexyme Inc. | CRTX | Senner Christopher J. Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-09 8:45 pm |
N/A 2032-06-07 |
Cortexyme Inc. | CRTX | RYAN UNA S Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-09 8:43 pm |
N/A 2032-06-07 |
Cortexyme Inc. | CRTX | Lamond David Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-09 8:41 pm |
N/A 2032-06-07 |
Cortexyme Inc. | CRTX | McLoughlin Margaret Director |
27,000 | $0 | 27,000 (Direct) |
View |
| 2022-06-06 Tax Withholding |
2022-06-08 4:13 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Monohon Ted Chief Accounting Officer & VP |
1,529 | $3.12 | 32,471 (Direct) |
View |
| 2022-06-06 Tax Withholding |
2022-06-08 4:10 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Holsinger Leslie EVP, Preclinical Development |
10,920 | $2.86 | 148,080 (Direct) |
View |
| 2022-06-06 Tax Withholding |
2022-06-08 4:09 pm |
N/A N/A |
Cortexyme Inc. | CRTX | McDowell Caryn Gordon Chief Legal & Adm. Officer |
6,700 | $2.8632 | 122,500 (Direct) |
View |
| 2022-05-19 Option Award(A) |
2022-05-27 5:37 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Smith Karen L. Chief Medical Officer |
170,354 | $0 | 194,690 (Direct) |
View |
| 2022-05-19 Option Award(A) |
2022-05-27 5:35 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Thye Dirk Chief Executive Officer |
216,322 | $0 | 280,911 (Direct) |
View |
| 2022-05-19 Option Award(A) |
2022-05-27 5:34 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Hannah Brendan Chief Business Officer |
113,569 | $0 | 129,793 (Direct) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:29 pm |
N/A 2022-03-27 |
Cortexyme Inc. | CRTX | Thye Dirk Chief Executive Officer |
2,250,630 | $0 | 2,250,630 (Direct) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:24 pm |
N/A 2032-03-27 |
Cortexyme Inc. | CRTX | Smith Karen L. Chief Medical Officer |
1,541,584 | $0 | 1,541,584 (Direct) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:17 pm |
N/A 2032-05-18 |
Cortexyme Inc. | CRTX | Low Philip S Director |
541,341 | $0 | 541,341 (Direct) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:09 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Lamond David Director |
200,002 | $0 | 3,883,660 (Indirect) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:07 pm |
N/A 2032-03-27 |
Cortexyme Inc. | CRTX | Hannah Brendan Chief Business Officer |
473,380 | $0 | 473,380 (Direct) |
View |